Organogenesis Holdings Inc. · NASDAQ:ORGO
Organogenesis — Investor Presentation (March 2025)
20 slides from Organogenesis's investor presentation, Mar 27, 2025
Slide 1: Investor Presentation March 2025
Exhibit 99.1 INVESTOR PRESENTATION March 2025
Slide 2: Forward Looking Statements & Other Important Cautions
FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements ma
Slide 3: Non-GAAP Financial Matters
NON-GAAP FINANCIAL MATTERS The Company has presented the following measures that are not measures of performance under accounting principles of generally accepted in the United States (“GAAP”): EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are not measurements of our financial performance u
Slide 4: Pioneering cellular and tissue-based innovations
PI PIO ON NE EER ERI IN NG G ce cell llu ular lar an and d t tis iss su ue e- -b ba as se ed d in inn no ov va at tio ion ns s Founded in 1985—our first Solving big Innovating in Validating with regenerative unmet patient transformative robust data and technology needs science clinical outcomes > >
Slide 5: Driven by Our Mission and Vision
DRIVEN BY OUR MISSION AND VISION Our Mission Our Vision Advancing Healing And Recovery A Force For Meaningful Change, Beyond Expectations Setting Higher Expectations in Healing And Recovery 5 5
Slide 6: Large Unmet Patient Needs
LARGE UNMET PATIENT NEEDS 1 2 3 >10M Chronic Wounds | >17M Acute Wounds | >32M Americans with Knee OA BIG PROBLEMS FUELED BY SECULAR Aging | Obesity | Trauma | Diabetes | Heart and Vascular Disease TAILWINDS REQUIRE INNOVATIVE Regenerative Therapies | Multiple Technologies | Delivered at Scale SOLUT
Slide 7: Market Opportunity Supporting Patients in Large Growing Markets
MARKET OPPORTUNITY SUPPORTING PATIENTS IN LARGE GROWING MARKETS ADVANCED WOUND CARE SURGICAL WOUND CARE OSTEOARTHRITIS 1 1 2 ~$11B ~$9B ~$7B ~$27B TOTAL ADDRESSABLE MARKET 7 1) Grand View Research (2021): Global Wound Care Market Report (2021-2028) 7 7 2) Grand View Research (2023): Osteoarthritis I
Slide 8: Leading Innovation: Multiple Technology Platforms
LEADING INNOVATION MULTIPLE TECHNOLOGY PLATFORMS Technology Platform Technology Platform Description Bioengineered Cellular ▪ Products produced from living allogeneic cells ▪ Wound and surgical regenerative therapies ▪ PMA and BLA regulatory pathway ▪ Products derived from human placental tissues an
Slide 9: Fueled by Science: Robust Regenerative Portfolio
FUELED BY SCIENCE ROBUST REGENERATIVE PORTFOLIO COLLAGEN / ANTIMICROBIAL LIVING CELLULAR PLACENTAL ALLOGRAFTS AMNIOTIC INJECTABLE • The Power of Plus: • The only fresh • Skin substitute • Dual-layered, • A complete • INVESTIGATIONAL Broad-spectrum placental membrane bioengineered with dehydrated hum
Slide 10: Years of Innovation, Evidence and Growth: Advanced Wound Care
40 YEARS OF INNOVATION, EVIDENCE and GROWTH ADVANCED WOUND CARE 1998 2016/2021 2017 2023 2021 2017 The only FDA- The only native A complete Dual-layered, The only fresh, The only fresh, living ECM scaffold + broad- approved living dehydrated dehydrated amniotic living cellular, cellular, human spect
Slide 11: Years of Innovation, Evidence and Growth: Surgical Wound Care
40 YEARS OF INNOVATION, EVIDENCE and GROWTH SURGICAL WOUND CARE 2016 2017 2022 2023 The only native ECM A complete dehydrated Micronized, native- 4-layer native ECM scaffold scaffold + broad-spectrum placental allograft structured collagen matrix + broad-spectrum PHMB PHMB antimicrobial antimicrobia
Slide 12: Key Data and Development to Date: ReNu
KEY DATA AND DEVELOPMENT TO DATE ® RENU ● Expect to submit BLA by end of 2025 ® ● ReNu achieved primary endpoint in first Phase 3 trial o Demonstrated a statistically significant reduction in knee osteoarthritis (OA) pain 1 at six months (p=0.0177) o Demonstrated a statistically significant maintena
Slide 13: Improved Patient Outcomes: ReNu Clinical Data
IMPROVED PATIENT OUTCOMES ® RENU CLINICAL DATA ENABLED ENTRY INTO PHASE 3 TRIALS 1 ▪ Patient-blinded, randomized, controlled clinical trial enrolled 200 patients ▪ Clinical significance in improvement of knee osteoarthritis pain to commercially available Hyaluronic acid (“HA”) and Saline 1 over 12 m
Slide 14: Rich Pipeline of Unique Technologies
IMPROVED PATIENT OUTCOMES RICH PIPELINE OF UNIQUE TECHNOLOGIES Potential Timeline for Commercial Launch 2024 2025 2026 2027 + PRODUCT • Expand portfolio offering to meet the needs of additional sites of care PuraPly and • Delivery of unique broad spectrum PHMB in surgical setting PuraPlyAM Line • De
Slide 15: Our Focus: Strategic Initiatives to Drive Growth
OUR FOCUS STRATEGIC INITIATIVES TO DRIVE GROWTH • Continued commercial ramp of placenta-based products Advanced Wound Care • Penetration of additional sites of care & clinical specialties • Leverage PuraPly brand to accelerate surgical/OR growth and Surgical Wound Care share capture • Expand surgica
Slide 16: Key Management: Highly Experienced Team
KEY MANAGEMENT HIGHLY EXPERIENCED TEAM WITH STRONG TRACK RECORD OF SUCCESS David Francisco, Gary Gillheeney, Patrick Bilbo, Chief Financial Officer President & CEO Chief Operating Officer ▪ Has been the CEO of Organogenesis since 2014▪ Has served as COO since 2017 ▪ Has served as CFO since 2021 ▪ Pr
Slide 17: Financials
FINANCIALS 17
Slide 18: Financial Profile: 2024 Financials
FINANCIAL PROFILE 2024 FINANCIALS 2024 Financial Performance 2024 % Increase/Decrease 2023 $482M +11% $433M Net Revenue Gross Profit $366M +12% $327M 76.0% +60bps 75.4% % Gross Profit $50M +17% $43M Adjusted EBITDA Adjusted EBITDA% 10.3% +50bps 9.8% 18 18
Slide 19: Financial Profile: Adjusted EBITDA Reconciliation
FINANCIAL PROFILE ADJUSTED EBITDA RECONCILIATION Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 ($, in thousands) Net income (loss) 7,673 (568) 861 4,945 Interest expense, net (61) 502 1,544 2,190 Income tax expense 2,580 (1,228) (3,668) 5,447 Depreciation and amortizati
Slide 20: Slide 20
Organogenesis Holdings — Investor Presentation (March 2025) on 6ix